Skip to content

Application of Deuterated Water (D2O) to Define the Etiology of Musculoskeletal Decline in Ageing and the Efficacy of Nutritional Supplementation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02505438
Enrollment
48
Registered
2015-07-22
Start date
2013-04-30
Completion date
Unknown
Last updated
2015-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Maintaining muscle mass and function is important in healthy ageing to maintain quality of life. Loss of muscle mass is major problem, as beyond the age \ 50, muscle mass declines by \ 1-2% a year. To prevent this loss, the investigators need to understand the mechanism regulating muscle mass as we age. In this project the investigators aim to determine these mechanisms using a new technique of heavy water ingestion, this allows measurement of multiple aspects of skeletal muscle mass metabolism e.g. protein synthesis, over long periods (6 weeks) as people go about their normal everyday activities. The investigators also aim to determine the influence of resistance exercise training on older muscle, as well as differences between men and women in muscle responses to exercise and nutrition HMB (beta-hydroxy-beta-methylbutyrate).

Interventions

BEHAVIORALExercise

Sponsors

The Dunhill Medical Trust
CollaboratorOTHER
University of Nottingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Young (18-30y) and old (60-75y) individuals who are generally healthy and recreationally active

Exclusion criteria

* Active cardiovascular disease * Cerebrovascular disease including previous stroke, aneurysm (large vessel or intracranial) * Respiratory disease including pulmonary hypertension or Chronic obstructive pulmonary disease, Hyper/ hypo parathyroidism, hyper/ hypothyroidism, * Cushing's disease, diabetes * Active inflammatory bowel disease * Renal disease * Malignancy * Recent steroid treatment (within 6 mo), or hormone replacement therapy Clotting dysfunction * Musculoskeletal or neurological disorders * Any disease requiring long-term drug prescriptions, including statins

Design outcomes

Primary

MeasureTime frameDescription
Muscle Protein Synthesis0-6 WeeksComparison of muscle protein synthesis between young and older individuals and in response to 6 weeks unilateral exercise training and supplementation
Muscle Strength0-6 WeeksMaximal voluntary contractions of the quadriceps will be performed (leg extension) in the trained and untrained legs. This will be performed at baseline and repeated throughout to monitor training progression

Countries

United Kingdom

Contacts

Primary ContactKen Smith, PhD
ken.Smith@nottingham.ac.uk
Backup ContactMatthew Brook
mzxmb2@nottingham.ac.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026